Connect with us

Business

Court documents shed new light on UK-Apple row over user data

Published

on

Court documents shed new light on UK-Apple row over user data


Graham FraserTechnology Reporter

Getty Images The Apple logo on a window, with a city scene including skyscrapers reflected on the windowGetty Images

The UK government may have wanted to force Apple to provide it with access to more customer data than previously thought, a court document has indicated.

A row erupted between the two after it emerged the Home Office asked the tech giant for the right access to highly encrypted user data stored via a service called Advanced Data Protection (ADP).

Now a court document suggests the request – made under legislation called the Investigatory Powers Act – could have also enabled the government to seek access to a wider range of Apple customer data.

It also suggests the government may still be seeking to access data of non-UK users, despite US officials saying last week it had dropped the demand.

The UK government and Apple have been approached for comment.

It is believed the UK government would only want to access this data if there was a risk to national security.

In February, it emerged the government had demanded to be able to access encrypted data stored by Apple users worldwide in its cloud service. It applied to all content stored using ADP service.

The tech uses end-to-end encryption, where only the account holder can access the data stored – even Apple itself cannot see it.

It was an opt-in service, and not all users choose to activate it.

While it makes your data more secure, it comes with a downside – it encrypts your data so heavily that it cannot be recovered if you lose access to your account.

It is unknown how many people choose to use ADP.

‘Back door’

After US politicians and privacy campaigners outlined their anger at the move, Apple decided to pull ADP from customers in the UK.

Now, a new court document has emerged from the Investigatory Powers Tribunal (IPT), an independent judicial body.

The IPT hears complaints from anyone who feels they have been the victim of unlawful action by a public body using covert investigative techniques.

It could also relate to the conduct of UK intelligence services including MI5 and MI6.

In this latest court filing, first reported by the Financial Times, it states Apple was given a technical capability notice (TCN) by the UK government at some point between late 2024 and early 2025.

It states the notice “applies to (although is not limited to) data covered by” ADP – it was previously understood the government’s demand was exclusively focused on data stored using the encryption technology.

The TCN to Apple also included “obligations to provide and maintain a capability to disclose categories of data stored within a cloud based backup service and to remove electronic protection which is applied to the data where that is reasonably practicable”.

The filing adds: “The obligations included in the TCN are not limited to the UK or users of the service in the UK; they apply globally in respect of the relevant data categories of all iCloud users.”

The new court document from the IPT is dated Wednesday, 27 August – eight days after Tulsi Gabbard, the US director of national intelligence, said the UK had withdrawn its controversial demand to access global Apple users’ data if required.

Gabbard said at the time in a post on X the UK had agreed to drop its instruction for the tech giant to provide a “back door” which would have “enabled access to the protected encrypted data of American citizens and encroached on our civil liberties”.

The BBC understood at the time Apple had not yet received any formal communication from either the US or UK governments.

It is not clear if this new court document simply refers to the UK government’s initial intention, or if indicates that the UK government has not yet dropped its wish to be able to access the data of Apple users from around the world, including those from the US.

Apple declined to comment, but says on its website that it views privacy as a “fundamental human right”.

Apple has previously said it would “never build a back door” in its products.

Cyber security experts agree that once such an entry point is in place, it is only a matter of time before bad actors also discover it.

No Western government has yet been successful in attempts to force big tech firms like Apple to break their encryption.

The US government has previously asked for this, but Apple has refused.

In 2016, Apple resisted a court order to write software which would allow US officials to access the iPhone of a gunman – though this was resolved after the FBI was able to successfully access the device.

Similar cases have followed, including in 2020, when Apple refused to unlock iPhones of a man who carried out a mass shooting at a US air base.

A green promotional banner with black squares and rectangles forming pixels, moving in from the right. The text says: “Tech Decoded: The world’s biggest tech news in your inbox every Monday.”



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site

Published

on

Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site


The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.

Mike Blake | Reuters

Eli Lilly on Monday said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect, building on efforts by the company and the Trump administration to make the medicine more accessible.

The announcement also comes weeks after chief rival Novo Nordisk unveiled additional discounts on the cash prices of its obesity and diabetes drugs. 

Starting Monday, cash-paying patients with a valid prescription can get the starting dose of Zepbound vials for as low as $299 per month on LillyDirect, down from a previous price of $349 per month. They can also access the next dose, 5 milligrams, for $399 per month and all other doses for $449 per month, down from $499 per month across those sizes. 

Zepbound carries a list price of roughly $1,086 per month. That price point, and spotty insurance coverage for weight loss drugs in the U.S., have been significant barriers to access for some patients. 

Eli Lilly’s announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to get and afford. The agreements will cut the prices the government pays for the drugs, introduce Medicare coverage of obesity drugs for the first time for certain patients and offer discounted medicines on the government’s new direct-to-consumer website launching in January, TrumpRx. 

But Eli Lilly’s deal with Trump centers around lowering the prices of a different form of Zepbound – a multi-dose pen – after it wins Food and Drug Administration approval. 

That means Eli Lilly’s Monday announcement around cutting prices on the existing single-dose vials could allow more patients to get discounted treatments more quickly. 

“We will keep working to provide more options — expanding choices for delivery devices and creating new pathways for access — so more people can get the medicines they need,” said Ilya Yuffa, president of Lilly USA and global customer capabilities, in a statement. 

Eli Lilly’s stock, which has climbed more than 36% this year, fell nearly 2% on Monday. Its meteoric rise due to the success of Zepbound and its diabetes injection Mounjaro vaulted it to becoming the first health-care company to hit a $1 trillion market value last month. Though cutting prices means lower revenue per medication sold, Eli Lilly’s sales — and shares — have continued to soar through past pricing announcements as demand balloons.

With single-dose vials, patients need to use a syringe and needle to draw up the medicine and inject it into themselves. Eli Lilly first introduced that form of Zepbound in August 2024. 

It’s unclear how many patients are currently using single-dose vials of Zepbound. But Eli Lilly previously said that direct-to-consumer sales now account for more than a third of new prescriptions of Zepbound. 

Novo Nordisk earlier this month lowered the price of its obesity drug Wegovy and diabetes treatment Ozempic for existing cash-paying patients to $349 per month from $499 per month. That excludes the highest dose of Ozempic. 

The company also launched a temporary introductory offer, which will allow new cash-paying patients to access the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment. 



Source link

Continue Reading

Business

OGRA Announces LPG Price Increase for December – SUCH TV

Published

on

OGRA Announces LPG Price Increase for December – SUCH TV



The Oil and Gas Regulatory Authority (OGRA) has approved a fresh increase in the price of liquefied petroleum gas (LPG), raising the cost for both domestic consumers and commercial users.

According to the notification issued, the LPG price has been increased by Rs7.39 per kilogram, setting the new rate at Rs209 per kg for December. As a result, the price of a domestic LPG cylinder has risen by Rs87.21, bringing the new price to Rs2,466.10.

In November, the price of LPG stood at Rs201 per kg, while the domestic cylinder was priced at Rs2,378.89.

The latest price hike is expected to put additional pressure on households already grappling with rising living costs nationwide.



Source link

Continue Reading

Business

Taxable Value Of Goods Surges 15% In Sep-Oct As GST Cuts Boost Consumption

Published

on

Taxable Value Of Goods Surges 15% In Sep-Oct As GST Cuts Boost Consumption


New Delhi: The taxable value of all supplies under GST surged by a robust 15 per cent during September-October this year, compared to the same period in 2024 due to sharp increase in consumption triggered by the tax rate cuts on goods across sectors that kicked in from September 22, according to official sources.

The growth in the same two-month period last year was 8.6 per cent. “This surge in taxable value during ‘Bachat Utsav’ demonstrates strong consumption uplift, stimulated by reduced rates and improved compliance behaviour,” a senior official said.

He pointed out that the growth has especially been strong in sectors where rate rationalisation was implemented, such as FMCG, pharma goods, food products, automobiles, medical devices and textiles. In these sectors, the taxable value of supplies has seen significantly higher growth, confirming that lower GST rates translated directly into higher consumer spending.

Add Zee News as a Preferred Source


“It vindicates our strategy that reducing rates on essentials and mass-use sectors would create demand-side buoyancy — a Laffer Curve–type demand uplift,” he explained.These trends confirm that GST next-gen reforms have not disrupted revenue stability, and that consumption-side buoyancy has begun to translate into higher taxable value in key sectors.

This growth is in value terms which means that since GST rates were lower, the growth in volume terms will be even higher. It is clearly visible that while the Next Gen Reforms resulted in significant Bachat — increased consumption, industry has been very proactive in passing on the GST savings to the final consumers and ensuring that there is no supply side deficiency.

As GDP private consumption data will be released much later, GST taxable value serves as the most reliable real-time proxy for consumption, and the current numbers clearly indicate sustained demand expansion, the official added. 



Source link

Continue Reading

Trending